<Anchor>
The nerves of the international community surrounding this vaccine are fierce. Following Germany, the European Union has also expressed skepticism about the exemption of intellectual property rights for vaccines, and the President of France has pointed out that export restrictions in the United States and the United Kingdom are more problematic.
Reporter Kim Yong-cheol on the report.
<Reporter>
EU Commissioner Von der Leien, who attended the unofficial EU summit, said an intellectual property waiver would not produce even one more vaccine. He said a different approach was needed.
[Ursula Pon der Reien/EU Executive Chairman: What we need now is an investment to share vaccines, export the vaccines we produce, and expand our vaccine manufacturing capabilities.]
French President Macron took a step back and regulated the export of vaccines in the US and the UK Said it was a problem.
[Emanuel Macron/President of France: Anglo-Saxon is blocking the movement of vaccines and raw materials. Now, 100% of the vaccines produced in the US are heading to the US market.]
Pfizer's chief executive has created an mRNA-type corona vaccine from a blank paper, and large-scale technical and financial support to increase production of 280 different raw materials required for vaccine manufacturing. He said it was necessary and expressed an objection to the exemption of intellectual property rights.
Vaccine manufacturing requires various raw materials, production technology, and know-how, but it is interpreted as being reluctant to disclose.
Germany's direct opposition to the exemption of intellectual property rights can be interpreted because Bio&Tech possesses core technology for mRNA vaccines with fewer side effects and good effects.
The mRNA vaccine produced by Pfizer, Modena, and Curebag is the first product implemented through genetic engineering and is evaluated to change the game of the pharmaceutical industry.
(Video editing: Jeong Seong-hoon)